These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Stoning a dead bird: advertising limits on approved new drugs. Strobos J Food Drug Law J; 1995; 50(4):533-51. PubMed ID: 10343018 [No Abstract] [Full Text] [Related]
6. Rules set for dissemination of off-label-use information. Miller JL Am J Health Syst Pharm; 1999 Feb; 56(3):204. PubMed ID: 10030500 [No Abstract] [Full Text] [Related]
7. MIMS is not a stand-alone resource. Donohoo EA Med J Aust; 2007 May; 186(9):484. PubMed ID: 17484718 [No Abstract] [Full Text] [Related]
8. The National Prescribing Service should lead. Stockigt JR Med J Aust; 2007 May; 186(9):484. PubMed ID: 17484717 [No Abstract] [Full Text] [Related]
9. Medicines and breastfeeding: information is available on safe use. Amir LH Med J Aust; 2007 May; 186(9):485. PubMed ID: 17484719 [No Abstract] [Full Text] [Related]
10. Inconsistency in DTCA practices by manufacturers: is it time to standardize print summaries? Sansgiry SS; Kawatkar AA Value Health; 2004; 7(2):216-7. PubMed ID: 15164811 [No Abstract] [Full Text] [Related]
11. Judging a book by its cover: the predicament with Canadian pharmacy advertisements and American consumers. Ballentine AJ; Lipowski EE J Am Pharm Assoc (2003); 2005; 45(6):740-3. PubMed ID: 16381422 [No Abstract] [Full Text] [Related]
12. Product information past perfect. Dowden JS Med J Aust; 2007 Jan; 186(2):51-2. PubMed ID: 17223760 [No Abstract] [Full Text] [Related]
13. Specialist societies can assist. Bach LA Med J Aust; 2007 May; 186(9):483. PubMed ID: 17484714 [No Abstract] [Full Text] [Related]
14. The Erice Statement on drug advertising to consumers. Orme M Eur J Clin Pharmacol; 2002 Nov; 58(8):S106-8. PubMed ID: 12536988 [No Abstract] [Full Text] [Related]
15. A consumer-empowered response to direct-to-consumer advertising of prescription drugs. Kemper DW; Mettler M Manag Care Q; 2002; 10(2):52-4. PubMed ID: 12148483 [TBL] [Abstract][Full Text] [Related]
16. Comment: the economics of direct-to-consumer advertising of prescription-only drugs: prescribed to improve consumer welfare? Rosenthal M J Health Serv Res Policy; 2004 Jan; 9(1):39-42; discussion 41-2. PubMed ID: 15006239 [No Abstract] [Full Text] [Related]
17. A defense of the learned intermediary doctrine. Goetz RB; Growdon KR Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470 [No Abstract] [Full Text] [Related]
18. Consumer-directed advertising of contraceptive drugs: the FDA, Depo-Provera, and product liability. Green W Food Drug Law J; 1995; 50(4):553-67. PubMed ID: 10343019 [No Abstract] [Full Text] [Related]
19. The First Amendment and FDA restrictions on off-label uses: the call for a new approach. Leghorn J; Brophy E; Rother P Food Drug Law J; 2008; 63(2):391-406. PubMed ID: 18561466 [No Abstract] [Full Text] [Related]
20. Promotional literature: how do we critically appraise? Shetty VV; Karve AV J Postgrad Med; 2008; 54(3):217-21. PubMed ID: 18626173 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]